Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes
June 23, 2022 08:00 ET
|
Aadi Bioscience
LOS ANGELES, June 23, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined...
Aadi Bioscience to Present at the Jefferies Global Healthcare Conference
June 01, 2022 08:00 ET
|
Aadi Bioscience
LOS ANGELES, June 01, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined...
Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications
May 31, 2022 08:00 ET
|
Aadi Bioscience
LOS ANGELES, May 31, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined...
Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual Meeting
May 26, 2022 17:10 ET
|
Aadi Bioscience
LOS ANGELES, May 26, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined...
Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference
May 18, 2022 07:00 ET
|
Aadi Bioscience
LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined...
UPDATE -- Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update
May 12, 2022 08:32 ET
|
Aadi Bioscience
FYARRO net product sales of $2.3 million in partial first quarterDosing of patients initiated in PRECISION 1, a Phase 2 tumor-agnostic registration-directed trial evaluating nab-sirolimus in TSC1 or...
Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update
May 12, 2022 07:00 ET
|
Aadi Bioscience
FYARRO net product sales of $2.3 million in partial first quarterDosing of patients initiated in PRECISION 1, a Phase 2 tumor-agnostic registration-directed trial evaluating nab-sirolimus in TSC1 or...
Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders
May 09, 2022 08:00 ET
|
Aadi Bioscience
Company enters into collaborations with leading next generation sequencing (NGS) companies to facilitate trial enrollment for PRECISION 1, the Company’s Phase 2 registrational trialCollaborations will...
Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO™ from Centers for Medicare and Medicaid Services
May 04, 2022 08:00 ET
|
Aadi Bioscience
LOS ANGELES, May 04, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined...
Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022
April 28, 2022 17:07 ET
|
Aadi Bioscience
LOS ANGELES, April 28, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for...